Global Neoantigen Cancer Vaccine Market Research Report 2022
SKU ID :QYR-21411095 | Published Date: 03-Aug-2022 | No. of pages: 92Description
TOC
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neoantigen Cancer Vaccine Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Personalized Vaccine
1.2.3 Off-the-shelf Neovaccines
1.3 Market by Application
1.3.1 Global Neoantigen Cancer Vaccine Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neoantigen Cancer Vaccine Market Perspective (2017-2028)
2.2 Neoantigen Cancer Vaccine Growth Trends by Region
2.2.1 Neoantigen Cancer Vaccine Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Neoantigen Cancer Vaccine Historic Market Size by Region (2017-2022)
2.2.3 Neoantigen Cancer Vaccine Forecasted Market Size by Region (2023-2028)
2.3 Neoantigen Cancer Vaccine Market Dynamics
2.3.1 Neoantigen Cancer Vaccine Industry Trends
2.3.2 Neoantigen Cancer Vaccine Market Drivers
2.3.3 Neoantigen Cancer Vaccine Market Challenges
2.3.4 Neoantigen Cancer Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neoantigen Cancer Vaccine Players by Revenue
3.1.1 Global Top Neoantigen Cancer Vaccine Players by Revenue (2017-2022)
3.1.2 Global Neoantigen Cancer Vaccine Revenue Market Share by Players (2017-2022)
3.2 Global Neoantigen Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neoantigen Cancer Vaccine Revenue
3.4 Global Neoantigen Cancer Vaccine Market Concentration Ratio
3.4.1 Global Neoantigen Cancer Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neoantigen Cancer Vaccine Revenue in 2021
3.5 Neoantigen Cancer Vaccine Key Players Head office and Area Served
3.6 Key Players Neoantigen Cancer Vaccine Product Solution and Service
3.7 Date of Enter into Neoantigen Cancer Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neoantigen Cancer Vaccine Breakdown Data by Type
4.1 Global Neoantigen Cancer Vaccine Historic Market Size by Type (2017-2022)
4.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Type (2023-2028)
5 Neoantigen Cancer Vaccine Breakdown Data by Application
5.1 Global Neoantigen Cancer Vaccine Historic Market Size by Application (2017-2022)
5.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Neoantigen Cancer Vaccine Market Size (2017-2028)
6.2 North America Neoantigen Cancer Vaccine Market Size by Country (2017-2022)
6.3 North America Neoantigen Cancer Vaccine Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Neoantigen Cancer Vaccine Market Size (2017-2028)
7.2 Europe Neoantigen Cancer Vaccine Market Size by Country (2017-2022)
7.3 Europe Neoantigen Cancer Vaccine Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size (2017-2028)
8.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Country (2017-2022)
8.3 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Neoantigen Cancer Vaccine Market Size (2017-2028)
9.2 Latin America Neoantigen Cancer Vaccine Market Size by Country (2017-2022)
9.3 Latin America Neoantigen Cancer Vaccine Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size (2017-2028)
10.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2017-2022)
10.3 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Neoantigen Cancer Vaccine Introduction
11.1.4 Roche Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.1.5 Roche Recent Development
11.2 Medimmune
11.2.1 Medimmune Company Detail
11.2.2 Medimmune Business Overview
11.2.3 Medimmune Neoantigen Cancer Vaccine Introduction
11.2.4 Medimmune Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.2.5 Medimmune Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck Neoantigen Cancer Vaccine Introduction
11.3.4 Merck Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.3.5 Merck Recent Development
11.4 Advaxis
11.4.1 Advaxis Company Detail
11.4.2 Advaxis Business Overview
11.4.3 Advaxis Neoantigen Cancer Vaccine Introduction
11.4.4 Advaxis Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.4.5 Advaxis Recent Development
11.5 Agenus
11.5.1 Agenus Company Detail
11.5.2 Agenus Business Overview
11.5.3 Agenus Neoantigen Cancer Vaccine Introduction
11.5.4 Agenus Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.5.5 Agenus Recent Development
11.6 Genocea
11.6.1 Genocea Company Detail
11.6.2 Genocea Business Overview
11.6.3 Genocea Neoantigen Cancer Vaccine Introduction
11.6.4 Genocea Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.6.5 Genocea Recent Development
11.7 Gritstone Oncology
11.7.1 Gritstone Oncology Company Detail
11.7.2 Gritstone Oncology Business Overview
11.7.3 Gritstone Oncology Neoantigen Cancer Vaccine Introduction
11.7.4 Gritstone Oncology Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.7.5 Gritstone Oncology Recent Development
11.8 Neon Therapeutics
11.8.1 Neon Therapeutics Company Detail
11.8.2 Neon Therapeutics Business Overview
11.8.3 Neon Therapeutics Neoantigen Cancer Vaccine Introduction
11.8.4 Neon Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.8.5 Neon Therapeutics Recent Development
11.9 Nouscom
11.9.1 Nouscom Company Detail
11.9.2 Nouscom Business Overview
11.9.3 Nouscom Neoantigen Cancer Vaccine Introduction
11.9.4 Nouscom Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.9.5 Nouscom Recent Development
11.10 OSE Immunotherapeutics
11.10.1 OSE Immunotherapeutics Company Detail
11.10.2 OSE Immunotherapeutics Business Overview
11.10.3 OSE Immunotherapeutics Neoantigen Cancer Vaccine Introduction
11.10.4 OSE Immunotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.10.5 OSE Immunotherapeutics Recent Development
11.11 Medigene
11.11.1 Medigene Company Detail
11.11.2 Medigene Business Overview
11.11.3 Medigene Neoantigen Cancer Vaccine Introduction
11.11.4 Medigene Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.11.5 Medigene Recent Development
11.12 Vaccibody
11.12.1 Vaccibody Company Detail
11.12.2 Vaccibody Business Overview
11.12.3 Vaccibody Neoantigen Cancer Vaccine Introduction
11.12.4 Vaccibody Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.12.5 Vaccibody Recent Development
11.13 Brightpath Biotherapeutics
11.13.1 Brightpath Biotherapeutics Company Detail
11.13.2 Brightpath Biotherapeutics Business Overview
11.13.3 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Introduction
11.13.4 Brightpath Biotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.13.5 Brightpath Biotherapeutics Recent Development
11.14 Geneos Therapeutics
11.14.1 Geneos Therapeutics Company Detail
11.14.2 Geneos Therapeutics Business Overview
11.14.3 Geneos Therapeutics Neoantigen Cancer Vaccine Introduction
11.14.4 Geneos Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.14.5 Geneos Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Tables & Figures
List of Tables
Table 1. Global Neoantigen Cancer Vaccine Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Personalized Vaccine
Table 3. Key Players of Off-the-shelf Neovaccines
Table 4. Global Neoantigen Cancer Vaccine Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 5. Global Neoantigen Cancer Vaccine Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Neoantigen Cancer Vaccine Market Size by Region (2017-2022) & (US$ Million)
Table 7. Global Neoantigen Cancer Vaccine Market Share by Region (2017-2022)
Table 8. Global Neoantigen Cancer Vaccine Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 9. Global Neoantigen Cancer Vaccine Market Share by Region (2023-2028)
Table 10. Neoantigen Cancer Vaccine Market Trends
Table 11. Neoantigen Cancer Vaccine Market Drivers
Table 12. Neoantigen Cancer Vaccine Market Challenges
Table 13. Neoantigen Cancer Vaccine Market Restraints
Table 14. Global Neoantigen Cancer Vaccine Revenue by Players (2017-2022) & (US$ Million)
Table 15. Global Neoantigen Cancer Vaccine Market Share by Players (2017-2022)
Table 16. Global Top Neoantigen Cancer Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neoantigen Cancer Vaccine as of 2021)
Table 17. Ranking of Global Top Neoantigen Cancer Vaccine Companies by Revenue (US$ Million) in 2021
Table 18. Global 5 Largest Players Market Share by Neoantigen Cancer Vaccine Revenue (CR5 and HHI) & (2017-2022)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Neoantigen Cancer Vaccine Product Solution and Service
Table 21. Date of Enter into Neoantigen Cancer Vaccine Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Neoantigen Cancer Vaccine Market Size by Type (2017-2022) & (US$ Million)
Table 24. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2017-2022)
Table 25. Global Neoantigen Cancer Vaccine Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 26. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2023-2028)
Table 27. Global Neoantigen Cancer Vaccine Market Size by Application (2017-2022) & (US$ Million)
Table 28. Global Neoantigen Cancer Vaccine Revenue Market Share by Application (2017-2022)
Table 29. Global Neoantigen Cancer Vaccine Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 30. Global Neoantigen Cancer Vaccine Revenue Market Share by Application (2023-2028)
Table 31. North America Neoantigen Cancer Vaccine Market Size by Country (2017-2022) & (US$ Million)
Table 32. North America Neoantigen Cancer Vaccine Market Size by Country (2023-2028) & (US$ Million)
Table 33. Europe Neoantigen Cancer Vaccine Market Size by Country (2017-2022) & (US$ Million)
Table 34. Europe Neoantigen Cancer Vaccine Market Size by Country (2023-2028) & (US$ Million)
Table 35. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2017-2022) & (US$ Million)
Table 36. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2023-2028) & (US$ Million)
Table 37. Latin America Neoantigen Cancer Vaccine Market Size by Country (2017-2022) & (US$ Million)
Table 38. Latin America Neoantigen Cancer Vaccine Market Size by Country (2023-2028) & (US$ Million)
Table 39. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2017-2022) & (US$ Million)
Table 40. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2023-2028) & (US$ Million)
Table 41. Roche Company Detail
Table 42. Roche Business Overview
Table 43. Roche Neoantigen Cancer Vaccine Product
Table 44. Roche Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 45. Roche Recent Development
Table 46. Medimmune Company Detail
Table 47. Medimmune Business Overview
Table 48. Medimmune Neoantigen Cancer Vaccine Product
Table 49. Medimmune Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 50. Medimmune Recent Development
Table 51. Merck Company Detail
Table 52. Merck Business Overview
Table 53. Merck Neoantigen Cancer Vaccine Product
Table 54. Merck Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 55. Merck Recent Development
Table 56. Advaxis Company Detail
Table 57. Advaxis Business Overview
Table 58. Advaxis Neoantigen Cancer Vaccine Product
Table 59. Advaxis Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 60. Advaxis Recent Development
Table 61. Agenus Company Detail
Table 62. Agenus Business Overview
Table 63. Agenus Neoantigen Cancer Vaccine Product
Table 64. Agenus Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 65. Agenus Recent Development
Table 66. Genocea Company Detail
Table 67. Genocea Business Overview
Table 68. Genocea Neoantigen Cancer Vaccine Product
Table 69. Genocea Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 70. Genocea Recent Development
Table 71. Gritstone Oncology Company Detail
Table 72. Gritstone Oncology Business Overview
Table 73. Gritstone Oncology Neoantigen Cancer Vaccine Product
Table 74. Gritstone Oncology Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 75. Gritstone Oncology Recent Development
Table 76. Neon Therapeutics Company Detail
Table 77. Neon Therapeutics Business Overview
Table 78. Neon Therapeutics Neoantigen Cancer Vaccine Product
Table 79. Neon Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 80. Neon Therapeutics Recent Development
Table 81. Nouscom Company Detail
Table 82. Nouscom Business Overview
Table 83. Nouscom Neoantigen Cancer Vaccine Product
Table 84. Nouscom Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 85. Nouscom Recent Development
Table 86. OSE Immunotherapeutics Company Detail
Table 87. OSE Immunotherapeutics Business Overview
Table 88. OSE Immunotherapeutics Neoantigen Cancer Vaccine Product
Table 89. OSE Immunotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 90. OSE Immunotherapeutics Recent Development
Table 91. Medigene Company Detail
Table 92. Medigene Business Overview
Table 93. Medigene Neoantigen Cancer VaccineProduct
Table 94. Medigene Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 95. Medigene Recent Development
Table 96. Vaccibody Company Detail
Table 97. Vaccibody Business Overview
Table 98. Vaccibody Neoantigen Cancer VaccineProduct
Table 99. Vaccibody Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 100. Vaccibody Recent Development
Table 101. Brightpath Biotherapeutics Company Detail
Table 102. Brightpath Biotherapeutics Business Overview
Table 103. Brightpath Biotherapeutics Neoantigen Cancer VaccineProduct
Table 104. Brightpath Biotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 105. Brightpath Biotherapeutics Recent Development
Table 106. Geneos Therapeutics Company Detail
Table 107. Geneos Therapeutics Business Overview
Table 108. Geneos Therapeutics Neoantigen Cancer VaccineProduct
Table 109. Geneos Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 110. Geneos Therapeutics Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neoantigen Cancer Vaccine Market Share by Type: 2021 VS 2028
Figure 2. Personalized Vaccine Features
Figure 3. Off-the-shelf Neovaccines Features
Figure 4. Global Neoantigen Cancer Vaccine Market Share by Application in 2021 & 2028
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Others Case Studies
Figure 8. Neoantigen Cancer Vaccine Report Years Considered
Figure 9. Global Neoantigen Cancer Vaccine Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 10. Global Neoantigen Cancer Vaccine Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Neoantigen Cancer Vaccine Market Share by Region: 2021 VS 2028
Figure 12. Global Neoantigen Cancer Vaccine Market Share by Players in 2021
Figure 13. Global Top Neoantigen Cancer Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neoantigen Cancer Vaccine as of 2021)
Figure 14. The Top 10 and 5 Players Market Share by Neoantigen Cancer Vaccine Revenue in 2021
Figure 15. North America Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 16. North America Neoantigen Cancer Vaccine Market Share by Country (2017-2028)
Figure 17. United States Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 18. Canada Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. Europe Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Europe Neoantigen Cancer Vaccine Market Share by Country (2017-2028)
Figure 21. Germany Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. France Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. U.K. Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Italy Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Russia Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Nordic Countries Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Asia-Pacific Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Asia-Pacific Neoantigen Cancer Vaccine Market Share by Region (2017-2028)
Figure 29. China Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Japan Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. South Korea Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Southeast Asia Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. India Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Australia Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Latin America Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Latin America Neoantigen Cancer Vaccine Market Share by Country (2017-2028)
Figure 37. Mexico Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Brazil Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Middle East & Africa Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Middle East & Africa Neoantigen Cancer Vaccine Market Share by Country (2017-2028)
Figure 41. Turkey Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Saudi Arabia Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Roche Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 44. Medimmune Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 45. Merck Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 46. Advaxis Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 47. Agenus Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 48. Genocea Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 49. Gritstone Oncology Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 50. Neon Therapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 51. Nouscom Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 52. OSE Immunotherapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 53. Medigene Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 54. Vaccibody Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 55. Brightpath Biotherapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 56. Geneos Therapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Companies
Roche
Medimmune
Merck
Advaxis
Agenus
Genocea
Gritstone Oncology
Neon Therapeutics
Nouscom
OSE Immunotherapeutics
Medigene
Vaccibody
Brightpath Biotherapeutics
Geneos Therapeutics
- PRICE
-
$2900$5800$4350Buy Now